Kyowa Kirin Co., Ltd. (TYO: 4151)

Market Cap	1.71T
Revenue (ttm)	476.00B
Net Income (ttm)	97.32B
Shares Out	526.52M
EPS (ttm)	181.64
PE Ratio	17.93
Forward PE	24.08
Dividend	58.00 (1.81%)
Ex-Dividend Date	Dec 27, 2024

Volume	822,100
Open	3,215.00
Previous Close	n/a
Day's Range	n/a
52-Week Range	2,266.50 - 3,350.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormon...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1949
• Employees: 5,974
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4151

Financial Performance

In 2023, Kyowa Kirin's revenue was 442.23 billion, an increase of 11.01% compared to the previous year's 398.37 billion. Earnings were 81.19 billion, an increase of 51.55%.